These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7863019)

  • 21. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients.
    Dencker SJ; Giös I; Mårtensson E; Nordén T; Nyberg G; Persson R; Roman G; Stockman O; Svärd KO
    Psychopharmacology (Berl); 1994 Feb; 114(1):24-30. PubMed ID: 7846204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate.
    Sassa T; Suhara T; Ikehira H; Obata T; Girard F; Tanada S; Okubo Y
    Psychiatry Clin Neurosci; 2002 Dec; 56(6):637-42. PubMed ID: 12485307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depot bromperidol decanoate for schizophrenia.
    Wong D; Adams CE; David A; Quraishi SN
    Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic properties of haloperidol decanoate.
    Alda M; Pavlovsky P; Kristofikova Z; Dufkova D
    Act Nerv Super (Praha); 1989 Apr; 31(1):38-9. PubMed ID: 2571223
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; De Vries R; Kaneko S
    J Clin Pharmacol; 2002 Oct; 42(10):1083-8. PubMed ID: 12362921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S; Farde L; Halldin C
    Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
    Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
    Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative bioavailability study of two haloperidol decanoate containing products.
    van Weringh G; Komen BJ; Thieme RE; van der Hoeven RT; Vos T
    Pharm World Sci; 1994 Dec; 16(6):243-7. PubMed ID: 7889022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haloperidol decanoate in the treatment of schizophrenia.
    Zapletálek M; Zbytovský J
    Act Nerv Super (Praha); 1989 Apr; 31(1):39-41. PubMed ID: 2571224
    [No Abstract]   [Full Text] [Related]  

  • 33. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
    Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
    Br J Clin Pharmacol; 2001 Sep; 52(3):265-71. PubMed ID: 11560558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
    Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
    Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
    Viala A; Aymard N; Leyris A; Caroli F
    Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic plasma levels.
    Van Putten T; Marder SR; Wirshing WC; Aravagiri M; Chabert N
    Schizophr Bull; 1991; 17(2):197-216. PubMed ID: 1679251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bromperidol decanoate (depot) for schizophrenia.
    Purgato M; Adams CE
    Cochrane Database Syst Rev; 2011 Sep; (9):CD001719. PubMed ID: 21901678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YW; Jann MW
    Schizophr Res; 1993 Mar; 9(1):35-40. PubMed ID: 8461270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
    Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
    J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.